← Eichor
Study identifier: NCT05786066 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

Condition: Depressive Disorder · Major Depressive Disorder · Bipolar Disorder  ·  Sponsor: Yale University

PhasePhase 2
Planned participants30
Who can joinAll sexes, 21 Years to 65 Years
Healthy volunteersNo

About this study

The purpose of this study is to test the hypothesis that the anti-depressant and anti-suicidal effects of the N-methyl-D-aspartate receptor (NMDAR) antagonist Ketamine is critically dependent on stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid receptors (AMPAR).

This description comes directly from the study's public registry record.

Talk to the study team

Naomi Driesen, PhD  ·  203-508-7765  ·  naomi.driesen@yale.edu

Always discuss trial participation with your own doctor first.

Locations (1)

VA Connecticut Healthcare SystemWest Haven, Connecticut, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05786066